The annual Australian Biotechnology Industry Position Survey (2014) shows a worrying trend: advanced manufacturing associated with this industry of the future is following traditional manufacturing and there has been a sharp increase in the number of companies heading overseas, the trade group AusBiotech warns.
The survey showed 73% of respondent companies are manufacturing: 44% in Australia and 54% overseas (with a cross over of 25% that manufacture both in Australia and overseas), prompting calls for further tax reform to enable Australia to be internationally competitive.
The survey, conducted by AusBiotech and supported by Grant Thornton Australia, saw a slight rise from last year in the number of companies manufacturing, in addition to a clear shift to more companies manufacturing overseas, now 54% up from the 36% recorded in 2013.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze